Eversense E3 CGM now connects with Apple Health!

YOUR PASS TO SAVE ON THE ONLY 6-MONTH* CGM

PAYMENT ASSISTANCE & SIMPLE SAVINGS

The EVERSENSE® PASS program can help make the EVERSENSE® E3 Continuous Glucose Monitoring System more affordable for you – now and in the future!

FOR ELIGIBLE PATIENTS:†
OFFERS TO GET STARTED AND KEEP YOU GOING

 
$99
FOR YOUR FIRST
SENSOR/TRANSMITTER

INTRO

Get started for only $99 for your initial sensor and transmitter and experience all the benefits the EVERSENSE® E3 CGM has to offer.

 

MAX
$600
OUT-OF-POCKET FOR FUTURE
SENSORS/TRANSMITTERS

ONGOING

Your out-of-pocket expenses will never exceed $600 for each subsequent sensor or sensor/transmitter combination and may be less depending on your insurance plan.

ELIGIBLE PATIENTS MUST MEET THE FOLLOWING REQUIREMENTS

  • Commercial insurance coverage (Medical/DME or Pharmacy)
  • Commercial insurance must cover EVERSENSE® E3
  • Valid prescription and completed Certificate of Medical Necessity Form (CMN)
  • Meet medical criteria for CGM (based on insurer's specific requirements

EXCLUSIONS

  • Government Insurance
  • Insurance plans that require purchase directly from HCPs



Get in touch to learn more about getting started on Eversense

Please complete your contact details and an Ascensia Diabetes Care representative will follow up with you shortly.

* The offers above only apply to the cost of the sensor and transmitter or sensor. They do not cover the cost of the insertion or removal procedure.
Limitations and Restrictions may apply. Ascensia Diabetes Care reserves the right to change or terminate this program at any time without notice.

Disclaimer

The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For safety information click here.

Eversense, Eversense E3 Continuous Glucose Monitoring and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, and the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.

Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.